Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verosudil in Exfoliation Syndrome and Glaucoma
NCT01936389Phase 2Completed
- Sponsor
- Robert Ritch, MD
- Start
- Sep 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of verosudil in exfoliation syndrome (XFS), ocular hypertension, pseudoexfoliative glaucoma (PEXG), sponsored by Robert Ritch, MD. Started Sep 2013; status: completed.
02
Drugs
verosudil
03
Conditions
exfoliation syndrome (XFS)ocular hypertensionpseudoexfoliative glaucoma (PEXG)
Beyond the preview
Go deeper on NCT01936389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01936389.